Reversing microtubule-directed chemotherapeutic drug resistance by co-delivering α2β1 inhibitor and paclitaxel with nanoparticles in ovarian cancer.
In conclusion, the expression of integrin α2β1 contributes to the MDCDs resistance, while applying E7820 combination treatment by MPEG-PLA nanoparticles could reverse the resistance. This article is protected by copyright. All rights reserved.
PMID: 31743535 [PubMed - as supplied by publisher]
Source: Cell Biology International - Category: Cytology Authors: Zheng W, Ge D, Meng G Tags: Cell Biol Int Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Cytology | Men | Nanotechnology | Ovarian Cancer | Ovaries | Toxicology